Methotrexate Related Compound C

CAS: 2410-93-7

Ref. 3D-CAA41093

Produktinformation

• Name: Methotrexate Related Compound C
• Synonyme: 10-Methylfolic acid, 10-Methylpteroylglutamic acid, <span class="text-smallcaps">L</span>-Glutamic acid, N-[4-[[(2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl]methylamino]benzoyl]-, <span class="text-smallcaps">L</span>-Glutamic acid, N-[4-[[(2-amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]methylamino]benzoyl]-, Glutamic acid, N-[p-[[(2-amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]methylamino]benzoyl]-, <span class="text-smallcaps">L</span>-, Glutamic acid, N-[p-[[(2-amino-4-hydroxy-6-pteridinyl)methyl]methylamino]benzoyl]-, Methopterin, Methopterine, N-(4-{[(2-amino-4-hydroxypteridin-6-yl)methyl](methyl)amino}benzoyl)glutamic acid, N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]methylamino]benzoyl]-<span class="text-smallcaps">L</span>-glutamic acid, N-[4-[[(2-Amino-4-hydroxy-6-pteridinyl)-methyl]methylamino]benzoyl]glutamic Acid, N¹⁰-Methylfolic acid, N¹⁰-Methylpteroylglutamic acid, NSC 107144, glutamic acid, N-[4-[[(2-amino-4-hydroxy-6-pteridinyl)methyl]methylamino]benzoyl]-

Beschreibung

Methotrexate Related Compound C (MRCC) is a drug that binds to the folate receptor and inhibits the synthesis of purines, pyrimidines, and dNTPs. It can be used in the treatment of autoimmune diseases, cancer, and hyperproliferative diseases. MRCC is not effective against acute lymphoblastic leukemia or myelodysplastic syndrome. MRCC has been shown to have therapeutic effects on skin cancer cells in tissue culture by inhibiting their proliferation. The mechanism of action may be due to its ability to inhibit protein kinase C activity. MRCC has been shown to be an effective inhibitor of lipid kinase in vitro and in vivo.

• Marke: Biosynth

Chemische Eigenschaften

• Molekulargewicht: 455.42 g/mol
• Formel: C₂₀H₂₁N₇O₆
• Reinheit: Min. 95%